| Followers | 1324 |
| Posts | 66548 |
| Boards Moderated | 12 |
| Alias Born | 01/24/2010 |
Tuesday, June 01, 2010 2:20:26 AM
Stocks i'm looking at this week GenVec, Inc.(NasdaqGM: GNVC)
After Hours: 0.58 Up 0.01 (1.93%) 7:54PM EDT
Liking the upside here and hope she pulls back for a nice entry.
_________________________________________________________
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III clinical trial for the treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic for the treatment of various cancers, including esophageal cancer, head and neck cancer, rectal cancer, and soft tissue sarcomas. In addition, its hearing and balance disorders program investigates delivery of the atonal gene in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and herpes simplex virus type 2. The company has a research collaboration and licensing agreement with Novartis Institutes for BioMedical Research, Inc. to discover and develop treatments for hearing loss and balance disorders. It also has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATH?S malaria vaccine initiative, the U.S. Naval Medical Research Center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.
After Hours: 0.58 Up 0.01 (1.93%) 7:54PM EDT
Liking the upside here and hope she pulls back for a nice entry.
_________________________________________________________
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III clinical trial for the treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic for the treatment of various cancers, including esophageal cancer, head and neck cancer, rectal cancer, and soft tissue sarcomas. In addition, its hearing and balance disorders program investigates delivery of the atonal gene in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and herpes simplex virus type 2. The company has a research collaboration and licensing agreement with Novartis Institutes for BioMedical Research, Inc. to discover and develop treatments for hearing loss and balance disorders. It also has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATH?S malaria vaccine initiative, the U.S. Naval Medical Research Center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
